Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company has ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Janssen opted not to continue with the first two integrin targets at the end of 2021 ... The collaboration was focused on development of alpha V beta 6 drugs for fibrotic diseases, including ...

This year, it has been joined by natalizumab (Tysabri; Elan/Biogen-Idec), a humanized antibody against α4 integrin ... and the drug label contains a black-box warning of the risk of serious ...

Telix Pharmaceuticals Ltd (ASX:TLX) is adding to its portfolio of early-stage drug candidates, in addition to a suite of other assets, through a $73 million asset buy agreement with antibody ...

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

These proteins, HER2 and α V β 6 integrin, are already known to independently ... more invasive through alternative pathways, meaning drugs designed to block α V β 6 or HER2 no longer prevent ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...